Nuvation Bio (NUVB) announced it has amended existing exclusive license agreement for safusidenib with Daiichi Sankyo (4568.T) to include Japan rights. The agreement, as amended, enables Nuvation Bio to expand its ongoing SIGMA study of safusidenib into Japan.
David Hung, CEO of Nuvation Bio, said: "With this agreement now final, we plan to expand the pivotal Phase 3 SIGMA study into Japan, continue to advance the robust global development of safusidenib, and pursue presentation and publication of longer-term data from the Phase 2 study to ensure the scientific community is up to date on these findings."
In pre-market trading on NYSE, Nuvation Bio shares are up 7.13 percent to $4.58.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.